Best of: PrEP: Ten Years On
Pharmacist Clint Hopkins displays the HIV prevention drug Truvada at Pucci's Pharmacy in Sacramento, Calif., Monday, Oct. 7, 2019. AP Photo/Rich Pedroncelli
Ten years ago this summer, a new chapter began in the AIDS pandemic. As with any treatment or preventative for something like HIV and AIDS, it can only be effective if it’s widely implemented. So after 10 years, is PrEP getting to the people who would most benefit from it? And how is Illinois doing generally in the fight against HIV and AIDS?
The 21st spoke to a panel of guests to discuss how Illinois is doing on HIV prevention and care and what the data is telling us about the uptake of PReP.
This conversation originally aired Aug. 18, 2022.
Guests:
Dr. Patrick Sullivan, M.D.
AIDSVU Principal Scientist
Jeffery Erdman
Associate Executive Director, Illinois Public Health Association
John Peller
President and CEO, AIDS Foundation Chicago
Arricka Cravens-Newingham
Assistant Chief of IDPH’s HIV/AIDS Section
#Prescribers, are you considering starting Truvada or Descovy for #HIVPrEP? Both are highly effective, but Descovy may be safer in cisgender men and transgender women at risk for #HIV, who are also at risk for bone or kidney disease. https://t.co/JQd6oHGjts #CDCTransHealth pic.twitter.com/DTSG5OBKUk
— Illinois ADVANCE (@IL_Advance) August 11, 2022
Prepared for web by Owen Henderson
Help shape our coverage on The 21st by joining our texting group and answering weekly questions. To join, text “TALK” to 217-803-0730 or sign up with your phone number below: